Bacteriophage virus-like particle vaccines for chlamydia trachomatis urogenital infection
Active Project Grant Awarded Last action
- Award ID
- R01AI166360
- Recipient
-
University Of New Mexico UEI G389MFAYJNG9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,393,525
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 78% complete
- Place of performance
- Albuquerque, NM 87131, USA
Award details come from USAspending.gov.
Description
- Abstract
- Chlamydia trachomatis is an obligate intracellular bacteria that is the most common bacterial sexually transmitted infection. Despite effective antibiotic treatment and screening programs, the prevalence of chlamydia continues to rise. Although the infection can be asymptomatic, some women experience serious long-term sequelae, including pelvic inflammatory disease, infertility, and ectopic pregnancy. For these reasons, a prophylactic vaccine against chlamydia is needed. However, significant gaps exist in our knowledge of the natural immune response to urogenital chlamydia trachomatis infection. In particular, the specificity of antibodies elicited during infection, their functions, and their protective capacity are not well understood. The overall goal of this research is to design prophylactic antibody-eliciting vaccines against urogenital chlamydia trachomatis infection. The objective of this proposal is to define the range of protective functions antibodies can have against chlamydia trachomatis infection of the female urogenital tract, and use this knowledge to create vaccines that can elicit those antibodies. Our working hypothesis is that antibody responses that target proteins known to be involved in adhesion and entry into host cells or mediate pathology in the reproductive tract will be protective against urogenital chlamydia trachomatis infection. In aim 1, we will engineer epitope-specific vaccine candidates that will elicit high titer antibodies to chlamydia trachomatis adhesion factors and define their immunogenicity in mouse immunization studies. In aim 2, we will investigate the specific functions of vaccine-elicited antibodies to neutralize chlamydia trachomatis infection in cell culture, mediate complement killing of chlamydia trachomatis, and facilitate uptake and killing by neutrophils. In aim 3, we will investigate the protective capacity of our vaccines in mouse models of chlamydia infection. We will investigate the bacterial burden in the upper reproductive tract, bacterial shedding, pathology, and male urogenital tract infection. Overall, these studies will define the role of epitope-specific antibodies in urogenital chlamydia trachomatis infection and lead to the identification of novel targets for chlamydia trachomatis vaccine design.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $378,653 | |
| Amendment | $371,365 | |
| Amendment | $38,312 | |
| Amendment | $38,312 | |
| Amendment | $344,805 | |
| Amendment | $344,805 | |
| Amendment | $344,805 | |
| Amendment | $383,117 | |
| Amendment | $383,117 | |
| Amendment | $383,117 | |
| Original award | $383,117 |
Show all 11
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Trustees Of Mount Holyoke College | $34,008 |
Quick answers
Who received award R01AI166360?
R01AI166360 was awarded to University Of New Mexico by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 6, 2022.
How much is award R01AI166360 worth?
$3,393,525 has been obligated on R01AI166360.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award